Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S291-S294, March 2004

Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation

  • T.Casanovas Taltavull

      Affiliations

    • Liver Transplant Unit, Hospital Universitario de Belvitge, L'Hospitalet de Llobregat, Barcelona, Spain
    • Corresponding Author InformationAddress reprint requests to Dr. Teresa Casanovas Taltavull, Liver Transplant Unit Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat 08907, Barcelona, Spain.

Abstract 

Over the last 20 years, immunosuppression protocols in liver transplant patients have been based on calcineurin inhibitors, such as cyclosporine (CsA). Currently, there are three outstanding clinical issues related to the use of CsA in the liver transplant setting that merit further attention: (1) dose adjustment according to 2-hour postdose (instead of trough) concentrations to improve efficacy and safety, (2) possible synergistic effect between CsA and antiviral treatments for recurrent posttransplant hepatitis C infection, and (3) preliminary results showing favorable outcomes after liver transplantation in HIV-positive patients receiving antiviral therapy.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0041-1345(03)01343-5

doi:10.1016/j.transproceed.2003.12.032

Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S291-S294, March 2004

Article Tools